MCID: HPT019
MIFTS: 60

Hepatic Encephalopathy

Categories: Liver diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Hepatic Encephalopathy

MalaCards integrated aliases for Hepatic Encephalopathy:

Name: Hepatic Encephalopathy 12 77 54 38 56 15 74
Portal-Systemic Encephalopathy 12
Encephalopathy, Hepatic 54
Hepatoencephalopathy 54

Classifications:



External Ids:

Disease Ontology 12 DOID:13413
KEGG 38 H01506
ICD9CM 36 572.2
MeSH 45 D006501
NCIt 51 C79596
SNOMED-CT 69 13920009
ICD10 34 K72
UMLS 74 C0019151

Summaries for Hepatic Encephalopathy

NIH Rare Diseases : 54 Hepatic encephalopathy is a syndrome observed in some patients with cirrhosis. It is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, when other known brain disease has been excluded. Signs and symptoms may be debilitating, and they can begin mildly and gradually, or occur suddenly and severely. They may include personality or mood changes, intellectual impairment, abnormal movements, a depressed level of consciousness, and other symptoms. There are several theories regarding the exact cause, but development of the condition is probably at least partially due to the effect of substances that are toxic to nerve tissue (neurotoxic), which are typically present with liver damage and/or liver disease. Treatment depends upon the severity of mental status changes and upon the certainty of the diagnosis.

MalaCards based summary : Hepatic Encephalopathy, also known as portal-systemic encephalopathy, is related to hepatic coma and alcoholic liver cirrhosis. An important gene associated with Hepatic Encephalopathy is TSPO (Translocator Protein), and among its related pathways/superpathways are Circadian entrainment and Immune response IL-23 signaling pathway. The drugs Rifaximin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood.

Wikipedia : 77 Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may... more...

Related Diseases for Hepatic Encephalopathy

Diseases related to Hepatic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
# Related Disease Score Top Affiliating Genes
1 hepatic coma 32.9 ALB F2 GPT TSPO
2 alcoholic liver cirrhosis 32.6 ALB F2 SLC17A5
3 liver cirrhosis 32.4 ALB F2 GPT SLC17A5
4 alcoholic hepatitis 31.6 ALB F2 GPT IL6 SLC17A5 TNF
5 acute liver failure 31.4 ALB F2 GC GPT SLC17A5 TSPO
6 infantile liver failure syndrome 1 30.7 ALB F2 GPT SLC17A5
7 hepatitis 30.5 F2 GPT SLC17A5 TNF
8 portal hypertension 30.4 ALB F2 GPT TNF
9 peritonitis 30.2 ALB F2 IL6 TNF
10 wilson disease 30.2 ALB F2 GPT
11 brain edema 30.0 ALB GLUL IL6 SLC1A2 SLC25A13
12 meningitis 30.0 ALB IL6 TNF
13 schistosomiasis 29.9 ALB F2 TNF
14 liver disease 29.9 ALB F2 GPT IL6 SLC17A5 SLC25A13
15 hepatitis b 29.8 ALB F2 GPT SLC17A5 TNF
16 fatty liver disease 29.7 IL6 SLC17A5 TNF
17 hepatitis e 29.6 ALB F2 GPT TNF
18 viral hepatitis 29.5 ALB F2 GPT SLC17A5 TNF
19 diabetes mellitus, noninsulin-dependent 29.4 ALB GPT IL6 SLC17A5 TNF
20 psychotic disorder 29.0 MAOB NOS1 S100B
21 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.5
22 combined oxidative phosphorylation deficiency 1 12.0
23 encephalopathy 11.4
24 congenital extrahepatic portosystemic shunt 11.4
25 3-hydroxyacyl-coa dehydrogenase deficiency 11.1
26 hepatic veno-occlusive disease 11.0
27 hepatorenal syndrome 11.0
28 antipyrine metabolism 10.4 ALB F2
29 non-a-e hepatitis 10.4 ALB F2
30 leukomalacia 10.4 IL6 TNF
31 scorpion envenomation 10.4 IL6 TNF
32 epstein-barr virus hepatitis 10.4 ALB F2
33 fournier gangrene 10.4 ALB F2
34 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL6 TNF
35 autoimmune myocarditis 10.4 IL6 TNF
36 critical limb ischemia 10.3 IL6 TNF
37 sudden sensorineural hearing loss 10.3 F2 IL6
38 abdominal tuberculosis 10.3 ALB F2
39 streptococcal toxic-shock syndrome 10.3 IL6 TNF
40 juvenile ankylosing spondylitis 10.3 IL6 TNF
41 cardiogenic shock 10.3 IL6 TNF
42 marburg hemorrhagic fever 10.3 F2 TNF
43 atypical depressive disorder 10.3 MAOA MAOB
44 burns 10.3 ALB TNF
45 null-cell leukemia 10.3 IL6 TNF
46 hypersensitivity reaction type iii disease 10.3 ALB IL6 TNF
47 keratoconjunctivitis sicca 10.3 ALB IL6 TNF
48 hemorrhagic fever with renal syndrome 10.3 ALB IL6 TNF
49 retinitis pigmentosa 55 10.3 IL6 TNF
50 pyelonephritis 10.3 ALB IL6 TNF

Comorbidity relations with Hepatic Encephalopathy via Phenotypic Disease Network (PDN): (show all 26)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Chronic Kidney Failure
Decubitus Ulcer Deficiency Anemia
Encephalopathy Esophageal Varix
Heart Disease Hepatitis
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Liver Disease
Neutropenia Portal Hypertension
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Urea Cycle Disorder

Graphical network of the top 20 diseases related to Hepatic Encephalopathy:



Diseases related to Hepatic Encephalopathy

Symptoms & Phenotypes for Hepatic Encephalopathy

MGI Mouse Phenotypes related to Hepatic Encephalopathy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 F2 GLS GLUL IL6 MAOA MAOB
2 homeostasis/metabolism MP:0005376 10.17 ALB F2 GC GLUL IL6 MAOA
3 mortality/aging MP:0010768 9.9 ALB F2 GLS GLUL IL6 NOS1
4 liver/biliary system MP:0005370 9.8 ALB GLUL IL6 NOS1 SLC25A13 TNF
5 nervous system MP:0003631 9.65 F2 GLUL IL6 MAOA MAOB NOS1
6 normal MP:0002873 9.23 ALB F2 GLS GLUL NOS1 S100B

Drugs & Therapeutics for Hepatic Encephalopathy

Drugs for Hepatic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 291)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173 46783403
2
Metformin Approved Phase 4 657-24-9 14219 4091
3
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
4
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
5
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
6
Magnesium oxide Approved Phase 4 1309-48-4 14792
7
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
8
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
9
Carvedilol Approved, Investigational Phase 4,Not Applicable 72956-09-3 2585
10
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
11
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142217-69-4 153941
12
Norfloxacin Approved Phase 4,Phase 3 70458-96-7 4539
13
Insulin Aspart Approved Phase 4 116094-23-6 16132418
14
Midodrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 133163-28-7, 42794-76-3 4195
15
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
16
Promethazine Approved, Investigational Phase 4,Not Applicable 60-87-7 4927
17
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
18
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
19
Histamine Approved, Investigational Phase 4 51-45-6 774
20
Diphenhydramine Approved, Investigational Phase 4,Not Applicable 147-24-0, 58-73-1 3100
21
Mannitol Approved, Investigational Phase 4,Not Applicable 69-65-8 453 6251
22
Terlipressin Approved, Investigational Phase 4,Not Applicable 14636-12-5 72081
23
Tolvaptan Approved Phase 4,Phase 3 150683-30-0 216237
24
Tranexamic Acid Approved Phase 4 1197-18-8 5526
25
chenodeoxycholic acid Approved Phase 4,Phase 3 474-25-9 10133
26
Ornithine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 3184-13-2, 70-26-8 6262
27
Calcium Approved, Nutraceutical Phase 4,Not Applicable 7440-70-2 271
28
Isoleucine Approved, Investigational, Nutraceutical Phase 4 73-32-5, 443-79-8 6306
29
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
30
Tenofovir Experimental, Investigational Phase 4,Phase 3,Not Applicable 147127-20-6 464205
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Hypoglycemic Agents Phase 4
36 N-Methylaspartate Phase 4,Phase 3,Phase 2,Not Applicable
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Not Applicable
39 Aspartic Acid Phase 4,Phase 3,Phase 2,Not Applicable
40 Excitatory Amino Acid Agonists Phase 4,Phase 3,Phase 2,Not Applicable
41 Anti-Anxiety Agents Phase 4,Not Applicable
42 Adjuvants, Anesthesia Phase 4,Not Applicable
43 GABA Modulators Phase 4,Phase 1,Phase 2,Not Applicable
44 Hypnotics and Sedatives Phase 4,Phase 2,Not Applicable
45 Tranquilizing Agents Phase 4,Not Applicable
46 GABA Agents Phase 4,Phase 1,Phase 2,Not Applicable
47 Anesthetics, General Phase 4,Not Applicable
48 Anesthetics Phase 4,Phase 2,Phase 1,Not Applicable
49 Anesthetics, Intravenous Phase 4,Not Applicable
50 Psychotropic Drugs Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 318)
# Name Status NCT ID Phase Drugs
1 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy Unknown status NCT03077217 Phase 4 Rifaximin
2 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
3 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
4 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
5 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
6 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
7 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
8 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
9 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
10 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
11 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
12 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
13 The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Unknown status NCT02695732 Phase 4 Carvedilol
14 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
15 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
16 Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
17 Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy Completed NCT01559519 Phase 4 Albumin
18 Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy Completed NCT00955500 Phase 4
19 Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate Completed NCT01847651 Phase 4 LOLA or placebo
20 Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
21 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
22 L-ornithine L-aspartate in Overt Hepatic Encephalopathy Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
23 Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
24 Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
25 The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Rifaximin and Lactulose
26 Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
27 Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
28 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
29 Ramelteon for Treatment of Insomnia in Cirrhosis Completed NCT03091738 Phase 4 Ramelteon Pill
30 Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis Completed NCT01943617 Phase 4 Entecavir;Thymosin-α
31 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
32 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
33 Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
34 PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Recruiting NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
35 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Recruiting NCT02401490 Phase 4 Human albumin;Placebo
36 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
37 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
38 Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients Recruiting NCT02849132 Phase 4 Entecavir
39 Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Recruiting NCT02190357 Phase 4 Rifaximin
40 Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment Recruiting NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
41 Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
42 Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After EVL Recruiting NCT03584087 Phase 4 Normal Saline;Terlipressin
43 Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load Not yet recruiting NCT02308319 Phase 4 Tenofovir disoproxil fumarate
44 Beta-blockers for Oesophageal Varices Not yet recruiting NCT03776955 Phase 4 Carvedilol
45 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
46 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
47 Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury Terminated NCT01824589 Phase 4
48 Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
49 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
50 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial Unknown status NCT00364689 Phase 3 Rifaximin alone, Rifaximin combined with Lactulose

Search NIH Clinical Center for Hepatic Encephalopathy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Hepatic Encephalopathy

Anatomical Context for Hepatic Encephalopathy

MalaCards organs/tissues related to Hepatic Encephalopathy:

42
Liver, Brain, Testes, Cortex, Colon, Bone, Eye

Publications for Hepatic Encephalopathy

Articles related to Hepatic Encephalopathy:

(show top 50) (show all 2955)
# Title Authors Year
1
Neurological Complications Occurring after Liver Transplantation: Role of Risk Factors, Hepatic Encephalopathy, and Acute (on Chronic) Brain Injury. ( 30697911 )
2019
2
Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: a propensity score-matching analysis. ( 30779213 )
2019
3
Adherence to Recommended Inpatient Hepatic Encephalopathy Workup. ( 30811321 )
2019
4
Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy. ( 30816877 )
2019
5
Hepatic encephalopathy: Lessons from preclinical studies. ( 30820267 )
2019
6
Peripheral inflammation induces neuroinflammation that alters neurotransmission and cognitive and motor function in hepatic encephalopathy: Underlying mechanisms and therapeutic implications. ( 30830722 )
2019
7
A Case of Catatonia Nearly Mistaken for Hepatic Encephalopathy. ( 30831063 )
2019
8
Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. ( 30848730 )
2019
9
Chemical exchange saturation transfer imaging in hepatic encephalopathy. ( 30856541 )
2019
10
Utility of the EncephalApp Stroop Test for Covert Hepatic Encephalopathy Screening in Chinese Cirrhotic Patients. ( 30861191 )
2019
11
Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy. ( 30862997 )
2019
12
Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample. ( 30863953 )
2019
13
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy. ( 30893082 )
2019
14
Glucuronidated bilirubin: Significantly increased in hepatic encephalopathy. ( 30905463 )
2019
15
Decreased Mean Kurtosis in the Putamen is a Diagnostic Feature of Minimal Hepatic Encephalopathy in Patients with Cirrhosis. ( 30626839 )
2019
16
The Psychomotor Vigilance Task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability. ( 30633946 )
2019
17
Early-Recurrent Overt Hepatic Encephalopathy Is Associated with Reduced Survival in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt Creation. ( 30638778 )
2019
18
Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. ( 30638914 )
2019
19
Modulation of sphingosine-1-phosphate receptor by FTY720 contributes in improvement of hepatic encephalopathy induced by bile duct ligation. ( 30660717 )
2019
20
Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multi-Center Study. ( 30668935 )
2019
21
Lactulose Management of Minimal Hepatic Encephalopathy: A Systematic Review. ( 30688711 )
2019
22
Predicting Overt Hepatic Encephalopathy for the Population with Cirrhosis. ( 30703852 )
2019
23
Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis. ( 30706253 )
2019
24
Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues. ( 30706419 )
2019
25
Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. ( 30706420 )
2019
26
L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic. ( 30706421 )
2019
27
Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology. ( 30706423 )
2019
28
Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy. ( 30706424 )
2019
29
L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. ( 30706425 )
2019
30
Functional Network-Based Statistics Reveal Abnormal Resting-State Functional Connectivity in Minimal Hepatic Encephalopathy. ( 30761070 )
2019
31
Hepatic encephalopathy and traffic accidents: Vigilance is needed! ( 30765121 )
2019
32
Special Section: Update in Hepatic Encephalopathy- Part III. ( 30765932 )
2019
33
Minimal/Covert Hepatic Encephalopathy - Impact of Comorbid Conditions. ( 30765943 )
2019
34
Prognostic Implications of Minimal/Covert Hepatic Encephalopathy: Large-scale Validation Cohort Studies. ( 30765944 )
2019
35
Hepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic Alteration. ( 30765945 )
2019
36
Role of Exercise in the Management of Hepatic Encephalopathy: Experience From Animal and Human Studies. ( 30765946 )
2019
37
How to Design a Multicenter Clinical Trial in Hepatic Encephalopathy. ( 30765947 )
2019
38
Bile Acids in Hepatic Encephalopathy. ( 30774268 )
2019
39
Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options. ( 30774483 )
2019
40
Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy. ( 30443767 )
2019
41
Protective role of chrysin on thioacetamide-induced hepatic encephalopathy in rats. ( 30500344 )
2019
42
Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing. ( 30506333 )
2019
43
Brain mitochondria as potential therapeutic targets for managing hepatic encephalopathy. ( 30578865 )
2019
44
Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. ( 30587923 )
2019
45
Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). ( 30606696 )
2019
46
Acetyl-L-carnitine for patients with hepatic encephalopathy. ( 30610762 )
2019
47
Corrigendum to "Impaired brain glymphatic flow in experimental hepatic encephalopathy" [J Hepatol 69 (2019) 40-49]. ( 30616987 )
2019
48
A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. ( 29668561 )
2019
49
Disrupted Brain Intrinsic Networks and Executive Dysfunction in Cirrhotic Patients without Overt Hepatic Encephalopathy. ( 29422882 )
2018
50
Comparison of prognostic systems in cirrhotic patients with hepatic encephalopathy ( 29914250 )
2018

Variations for Hepatic Encephalopathy

Expression for Hepatic Encephalopathy

LifeMap Discovery
Genes differentially expressed in tissues of Hepatic Encephalopathy patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PSPH phosphoserine phosphatase Brain - 4.35 0.000
Search GEO for disease gene expression data for Hepatic Encephalopathy.

Pathways for Hepatic Encephalopathy

Pathways related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 GLS GLUL MAOA MAOB NOS1 SLC1A2
2
Show member pathways
12.38 F2 IL6 NOS1 TNF
3
Show member pathways
12.04 ALB F2 IL6 TNF
4 11.86 ALB S100B TSPO
5
Show member pathways
11.84 F2 IL6 TNF
6 11.81 IL6 NOS1 TNF
7
Show member pathways
11.77 NOS1 SLC1A2 TNF
8 11.76 IL6 MAOA TNF
9 11.59 GLS GLUL MAOA
10
Show member pathways
11.3 MAOA MAOB NOS1
11
Show member pathways
11.07 MAOA NOS1 TNF
12
Show member pathways
10.94 GLS GLUL GPT
13 10.86 IL6 TNF
14
Show member pathways
10.69 MAOA MAOB
15 10.68 GLS GLUL GPT
16 10.64 MAOA MAOB
17
Show member pathways
10.59 MAOA MAOB
18
Show member pathways
10.34 GLUL SLC1A2
19
Show member pathways
10.34 GLS GLUL GPT NOS1

GO Terms for Hepatic Encephalopathy

Cellular components related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 ALB F2 GC GPT IL6 S100B
2 mitochondrion GO:0005739 9.17 GLS GLUL MAOA MAOB NOS1 SLC25A13

Biological processes related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.78 IL6 S100B TNF TSPO
2 positive regulation of chemokine production GO:0032722 9.49 IL6 TNF
3 glutamate secretion GO:0014047 9.46 GLS SLC1A2
4 L-glutamate transmembrane transport GO:0015813 9.43 SLC1A2 SLC25A13
5 response to glucocorticoid GO:0051384 9.43 IL6 S100B TNF
6 neurotransmitter catabolic process GO:0042135 9.4 MAOA MAOB
7 negative regulation of lipid storage GO:0010888 9.37 IL6 TNF
8 dopamine catabolic process GO:0042420 9.32 MAOA MAOB
9 positive regulation of neuroinflammatory response GO:0150078 9.16 IL6 TNF
10 cellular amino acid biosynthetic process GO:0008652 9.13 GLS GLUL GPT
11 positive regulation of glial cell proliferation GO:0060252 8.8 IL6 TNF TSPO

Molecular functions related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 L-glutamate transmembrane transporter activity GO:0005313 8.96 SLC1A2 SLC25A13
2 primary amine oxidase activity GO:0008131 8.62 MAOA MAOB

Sources for Hepatic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....